Bio Break: Why Don’t We Have a Cortisol-Sensing Wearable Yet?
In this Bio Break episode, Nick Allan and Joris van der Heijden tackle a question many tech and health enthusiasts have wondered for years: Where is my cortisol-sensing wearable? Nick shares a nostalgic story of reading about futuristic wearable technology in Popular Mechanics as a child — devices that would one day monitor biomarkers like cortisol to track stress and overall health. Now, decades later, he and Joris break down why such a wearable device still hasn’t become a reality.
Joris explains that although cortisol biosensors and other advanced wearable diagnostics often show up in academic research, turning those scientific breakthroughs into viable consumer products is a much bigger challenge. First, there’s the technical difficulty of converting a sensitive laboratory assay for cortisol into a fully automated, real-time wearable device that could be used reliably outside of controlled lab settings. Measuring something like cortisol, potentially via interstitial fluid or sweat, involves complex fluidic and sensing systems that must function accurately and consistently on a wearable platform.
Second — and often the biggest hurdle — is scaling up manufacturing. Developing a biosensor consumable that can be produced in the millions, perform reliably for every user, and endure various shipping and environmental conditions is an enormous undertaking. Joris points out that ensuring batch-to-batch consistency for sensitive biological components is one of the toughest parts of commercializing wearable biosensor technology. Add to that the need to meet stringent regulatory standards for medical wearables, and it’s easy to see why many promising lab innovations never make it to market.
In short, the journey from a cortisol-sensing concept to a commercial wearable health device requires not only cutting-edge science but also significant investment, manufacturing expertise, and regulatory strategy.
Why Don’t We Have a Cortisol-Sensing Wearable Yet?
For Startups or Founders developing a device that incorporates novel technology or is like nothing else, the FDA breakthrough medical device program may be the best regulatory option. Learn more.
Related Resources
Connected health devices are multiplying fast. We examine the gap between remote monitoring’s promise and its reality.
Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.